12:00 AM
Feb 14, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

TMC649128: Phase Ia started

Johnson & Johnson's Tibotec Pharmaceuticals unit began a double-blind, placebo-controlled, Belgium Phase Ia trial evaluating single ascending-doses of oral TMC649128 in about 54 healthy volunteers....

Read the full 104 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >